According to Novo Nordisk, the drug Ozempic is at risk of running out of pharmacies in Brazil in the first quarter of 2023. The drug is approved by Anvisa to treat cases of uncontrolled type 2 diabetes, but it has become increasingly popular among patients. treating obesity.
The possible lack of Ozempic FlexTouch, which is marketed in a 1 mg presentation, is the result of a greater demand than expected by the drug manufacturer.
questioned by metropolisesthe pharmaceutical says it notified the Brazilian health authority regarding product supply restrictions in January 2023, but intends to normalize sales in the second quarter of that year.
“The resupply of distributors, wholesalers and pharmacies in the country should be normalized during the second quarter of 2023. Novo Nordisk is investing intensely and continuously to resolve the situation and significantly increase the annual production of Ozempic”, it says, in a note.
Novo Nordisk adds that it is not possible to trace the intended use of the product by the patient, but does not promote or encourage any off-label use of its products.
Get news from metropolises on your Telegram and stay on top of everything! Just access the channel: https://t.me/metropolesurgente.
